WAVE LIFE SCIENCES LTD. (1U5) - Total Liabilities
Based on the latest financial reports, WAVE LIFE SCIENCES LTD. (1U5) has total liabilities worth €71.81 Million EUR (≈ $83.96 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset growth rate of WAVE LIFE SCIENCES LTD. to track the company's year-over-year net asset growth rate.
WAVE LIFE SCIENCES LTD. - Total Liabilities Trend (2021–2025)
This chart illustrates how WAVE LIFE SCIENCES LTD.'s total liabilities have evolved over time, based on quarterly financial data.
WAVE LIFE SCIENCES LTD. Competitors by Total Liabilities
The table below lists competitors of WAVE LIFE SCIENCES LTD. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sabine Royalty Trust
NYSE:SBR
|
USA | $1.43 Million |
|
Suzhou Hailu Heavy Industry Co Ltd
SHE:002255
|
China | CN¥1.94 Billion |
|
Sano Bruno's Enterprises Ltd
TA:SANO1
|
Israel | ILA466.68 Million |
|
Hunan Yujing Machinery Co Ltd Class A
SHE:002943
|
China | CN¥1.86 Billion |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
|
China | CN¥1.83 Billion |
|
Sino Wealth Electronic Ltd
SHE:300327
|
China | CN¥328.69 Million |
|
Henan Yicheng New Energy Co Ltd
SHE:300080
|
China | CN¥8.94 Billion |
|
Rastar Environmental Protection Materials Co.Ltd.
SHE:300834
|
China | CN¥1.40 Billion |
Liability Composition Analysis (2021–2025)
This chart breaks down WAVE LIFE SCIENCES LTD.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see WAVE LIFE SCIENCES LTD. (1U5) total market value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 11.26 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.14 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.12 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how WAVE LIFE SCIENCES LTD.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for WAVE LIFE SCIENCES LTD. (2021–2025)
The table below shows the annual total liabilities of WAVE LIFE SCIENCES LTD. from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €120.14 Million ≈ $140.46 Million |
-15.80% |
| 2024-12-31 | €142.69 Million ≈ $166.82 Million |
-39.36% |
| 2023-12-31 | €235.32 Million ≈ $275.11 Million |
+22.90% |
| 2022-12-31 | €191.48 Million ≈ $223.86 Million |
+9.72% |
| 2021-12-31 | €174.51 Million ≈ $204.02 Million |
-- |
About WAVE LIFE SCIENCES LTD.
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent diso… Read more